MLICM
RIGL icon

Metropolitan Life Insurance Company (MetLife)’s Rigel Pharmaceuticals RIGL Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-438
Closed -$6.49K – 1675
2024
Q1 		$6.49K Buy
438
+47
+12% +$633 ﹤0.01% 2226
2023
Q4 		$5.67K Sell
391
-555
-59% -$5.67K ﹤0.01% 2278
2023
Q3 		$10.2K Hold
946
– – ﹤0.01% 2197
2023
Q2 		$12.2K Hold
946
– – ﹤0.01% 2193
2023
Q1 		$12.5K Sell
946
-130
-12% -$2.06K ﹤0.01% 2079
2022
Q4 		$16.1K Buy
1,076
+21
+2% +$193 ﹤0.01% 2109
2022
Q3 		$12.5K Buy
1,055
+868
+464% +$11.7K ﹤0.01% 2236
2022
Q2 		$2.11K Sell
187
-986
-84% -$19.8K ﹤0.01% 2356
2022
Q1 		$35.1K Sell
1,173
-3,590
-75% -$97.2K ﹤0.01% 1794
2021
Q4 		$126K Buy
4,763
+412
+9% +$12.4K ﹤0.01% 2340
2021
Q3 		$158K Buy
4,351
+654
+18% +$25.7K ﹤0.01% 2257
2021
Q2 		$160K Sell
3,697
-1,295
-26% -$48.9K ﹤0.01% 2309
2021
Q1 		$171K Buy
4,992
+183
+4% +$7.25K ﹤0.01% 2133
2020
Q4 		$168K Sell
4,809
-125
-3% -$3.62K ﹤0.01% 2046
2020
Q3 		$118K Sell
4,934
-814
-14% -$20K ﹤0.01% 2121
2020
Q2 		$105K Buy
5,748
+10
+0.2% +$180 ﹤0.01% 2229
2020
Q1 		$89.5K Sell
5,738
-221
-4% -$4.7K ﹤0.01% 2098
2019
Q4 		$128K Buy
5,959
+1,638
+38% +$33.7K ﹤0.01% 2182
2019
Q3 		$80.8K Sell
4,321
-886
-17% -$18.3K ﹤0.01% 2421
2019
Q2 		$136K Hold
5,207
– – ﹤0.01% 2151
2019
Q1 		$134K Buy
5,207
+220
+4% +$5.03K ﹤0.01% 2148
2018
Q4 		$115K Hold
4,987
– – ﹤0.01% 2180
2018
Q3 		$160K Hold
4,987
– – ﹤0.01% 2160
2018
Q2 		$141K Buy
4,987
+392
+9% +$13.9K ﹤0.01% 2143
2018
Q1 		$163K Buy
4,595
+1,226
+36% +$49.1K ﹤0.01% 2027
2017
Q4 		$131K Sell
3,369
-12,813
-79% -$488K ﹤0.01% 2159
2017
Q3 		$411K Buy
16,182
+6,853
+73% +$167K ﹤0.01% 1817
2017
Q2 		$255K Hold
9,329
– – ﹤0.01% 2182
2017
Q1 		$309K Buy
9,329
+3,456
+59% +$88.1K ﹤0.01% 1978
2016
Q4 		$140K Sell
5,873
-232
-4% -$6.64K ﹤0.01% 2496
2016
Q3 		$224K Sell
6,105
-694
-10% -$19.9K ﹤0.01% 2266
2016
Q2 		$152K Hold
6,799
– – ﹤0.01% 2512
2016
Q1 		$141K Buy
6,799
+81
+1% +$2K ﹤0.01% 2365
2015
Q4 		$204K Buy
6,718
+68
+1% +$2.06K ﹤0.01% 2258
2015
Q3 		$164K Buy
6,650
+4,060
+157% +$121K ﹤0.01% 2414
2015
Q2 		$83K Sell
2,590
-4,686
-64% -$179K ﹤0.01% 2627
2015
Q1 		$260K Sell
7,276
-374
-5% -$10.3K ﹤0.01% 1919
2014
Q4 		$174K Buy
+7,650
New +$155K ﹤0.01% 2507
2014
Q3 		– Sell
-3,228
Closed -$117K – 2714
2014
Q2 		$117K Sell
3,228
-4,100
-56% -$139K ﹤0.01% 2672
2014
Q1 		$284K Hold
7,328
– – ﹤0.01% 2224
2013
Q4 		$209K Hold
7,328
– – ﹤0.01% 2441
2013
Q3 		$262K Buy
7,328
+2,456
+50% +$89.6K ﹤0.01% 2216
2013
Q2 		$163K Buy
+4,872
New +$221K ﹤0.01% 2490

Other funds holding RIGL

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s RIGL Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 438 shares — an estimated $6.49K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in RIGL in Q2 2013 and held it in 43 quarters. The position peaked at $411K in Q3 2017. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 438 Rigel Pharmaceuticals shares in Q2 2024, an estimated $6.49K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Rigel Pharmaceuticals in Q2 2013 and held it in 43 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Rigel Pharmaceuticals position peaked at $411K in Q3 2017.
  • 91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.